Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV‑2

The Bacillus Calmette–Guerin vaccine is still widely used in the developing world. The vaccination prevents infant death not only from tuberculosis but also from unrelated infectious agents, especially respiratory tract infections and neonatal sepsis. It is proposed that these off-target protective...

Full description

Saved in:
Bibliographic Details
Published in:Journal of proteome research 2020-11, Vol.19 (11), p.4649-4654
Main Authors: Glisic, Sanja, Perovic, Vladimir R, Sencanski, Milan, Paessler, Slobodan, Veljkovic, Veljko
Format: Article
Language:English
Subjects:
Bacterial Proteins - chemistry
Bacterial Proteins - immunology
BCG Vaccine - chemistry
BCG Vaccine - immunology
Betacoronavirus - chemistry
Betacoronavirus - immunology
Coronavirus Infections - immunology
Coronavirus Infections - prevention & control
COVID-19
COVID-19 Vaccines
Drug Repositioning
Humans
Mycobacterium bovis - chemistry
Mycobacterium bovis - immunology
Pandemics - prevention & control
Pneumonia, Viral - immunology
Pneumonia, Viral - prevention & control
Proteome - chemistry
Proteome - immunology
SARS-CoV-2
Viral Vaccines - chemistry
Viral Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Bacillus Calmette–Guerin vaccine is still widely used in the developing world. The vaccination prevents infant death not only from tuberculosis but also from unrelated infectious agents, especially respiratory tract infections and neonatal sepsis. It is proposed that these off-target protective effects of the BCG vaccine are mediated by the general long-term boosting of innate immune mechanisms, also termed “trained innate immunity”. Recent studies indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs and encourage the initiation of several clinical studies with the expectation that revaccination with BCG could reduce the incidence and severity of COVID-19. Here, presented results from the bioinformatics analysis of the Mycobacterium bovis (strain BCG/Pasteur 1173P2) proteome suggests four immunodominant antigens that could induce an immune response against SARS-CoV-2.
ISSN:1535-3893
1535-3907
DOI:10.1021/acs.jproteome.0c00410